Pilot Study to Evaluate Fatigue and Fatigability Profiles and Their Impact on Walking and Balance in Patients With Charcot-Marie-Tooth Type 1A Disease Using a Global Approach in Comparison to Healthy Volunteers
FatMobCMT1A
2 other identifiers
interventional
44
1 country
1
Brief Summary
Charcot-Marie-Tooth disease type 1A is the most common form of inherited neuropathy that causes peripheral nerve damage in all four limbs. In addition to the well-known distal motor and sensory symptoms, fatigue is one of the most common symptoms reported by patients. However, there is very little scientific data on this topic. Fatigue is associated with changes in mobility and quality of life. This study investigates the magnitude and impact of fatigue on patients' sensory-motor function and mobility (standing and walking). Fatigue is a complex phenomenon. It is therefore essential to assess all the factors that may be at the origin of this symptom (perceived fatigue and fatigability) using innovative and robust assessment methods. These methods are based on quantitative non-invasive neurophysiologic measures (electromyography and transcranial magnetic stimulation). The patients can quantify and identify more precisely the origin of fatigability (peripheral and central). This objective approach needs to be combined with the usual methods of measuring fatigue using valid and reliable patient-reported outcome measures. A quantitative measure of movement during walking must also be included to assess changes in fatigue during functional movement. To quantify the proportion of fatigue associated with CMT1A, the investigators chose to compare data from patients with those of healthy subjects matched for age, height and lean body mass. A better understanding of the role of fatigue in limiting walking and balance capacities in these patients will allow the investigators to refine the inpatient and outpatient management.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 19, 2025
CompletedFirst Posted
Study publicly available on registry
July 15, 2025
CompletedStudy Start
First participant enrolled
February 20, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 20, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
ExpectedFebruary 19, 2026
July 1, 2025
Same day
March 19, 2025
February 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Fatigability profile
Difference in isometric force developed by the knee extensors (assessment of overall neuromuscular fatigue) before and after a tiring exercise (stress test), during a maximum voluntary contraction, expressed in N.m-1, assessed on an isokinetic dynamometer (CONTREX®), compared between patients with mCMT1A and healthy volunteers.
7 days
Study Arms (2)
Charcot Marie Tooth type 1A
EXPERIMENTALCLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION): * Perceived fatigue * Mental functions * Sensory functions and pain * Neuromusculoskeletal and movement-related functions * Functions of the cardiovascular and respiratory systems o Exercise stress test * Fatigability (neuromuscular fatigue) * Lower limbs * Maximum voluntary strength * Study of the central and peripheral components of fatigue ACTIVITIES AND PARTICIPATION * Mobility * Clinical standard tests for balance and walking * Quantified motion analysis * Activity level * Quality of life
Healthy subjects matched for age, height and lean body mass.
ACTIVE COMPARATORIdentical to patient, except for Charcot-Marie-Tooth specific tests
Interventions
Tip: Ensure that this name matches the name used in the associated Arm Description. CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION): * Perceived fatigue * Mental functions * Sensory functions and pain * Neuromusculoskeletal and movement-related functions * Functions of the cardiovascular and respiratory systems o Exercise stress test * Fatigability (neuromuscular fatigue) * Lower limbs * Maximum voluntary strength and power * Study of the central and peripheral components of fatigue ACTIVITIES AND PARTICIPATION * Mobility * Clinical standard tests for balance and walking * Quantified motion analysis * Activity level Quality of life The same evaluation tests will be performed on patients and healthy volunteer controls
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years and \< 75 years
- Patient with mCMT1A confirmed by genetic analysis (based on data recorded in the patient file)
- Patient able to walk a minimum of 200 metres without a break, with or without equipment and/or technical aids (collected during questioning)
- Patient able to get on and off a cycloergometer safely without assistance or with minimal assistance
- Patient affiliated to a health insurance scheme or beneficiary of such a scheme
- Age ≥ 18 years and \< 75 years
- Subject affiliated to or benefiting from a health insurance scheme
- Subject who has had a cardiological work-up prior to stress testing (ECG and cardiac ultrasound less than 6 months old) or for whom a work-up is scheduled prior to the procedure.
You may not qualify if:
- Patients with all other forms of neuropathy (HNPP, other types of CMT, secondary neuropathies)
- Patients with any of the following
- An associated neurological disease other than mCMT1A
- Severe joint disease of the lower limbs
- Contraindication to isokinetic testing
- Contraindication to an exercise stress test and exercise reconditioning program
- A contraindication to Transcranial Magnetic Stimulation (TMS) : epilepsy, intracranial metallic foreign body, hearing aid or cochlear implant, unstable skull bone fracture, deafness, etc.
- Pregnant or breastfeeding or planning to become pregnant within the next 4 months
- BMI \> 35 kg/m2
- Patient unable to give informed consent, unable to understand informed information
- Subject under court protection
- Subject under guardianship or curatorship
- History of neurological disease
- Severe joint damage in the lower limbs
- Any of the following
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Pôle de médecine physique et de réadaptation, Hôpital de Hautepierre, Strasbourg Centre de référence des maladies neuromusculaires, Institut Universitaire de Réadaptation Clémenceau, Strasbourg
Strasbourg, 67000, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 19, 2025
First Posted
July 15, 2025
Study Start
February 20, 2026
Primary Completion
February 20, 2026
Study Completion (Estimated)
February 1, 2028
Last Updated
February 19, 2026
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share